238 related articles for article (PubMed ID: 28707550)
1. Rising Cost of Anticancer Medications in the United States.
Jackson K; Nahata MC
Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy team involvement in navigating the revenue cycle for high-cost medications in patients with cancer.
Shank BR; Nguyen PAA; Pherson EC
Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP470-SP473. PubMed ID: 29087665
[No Abstract] [Full Text] [Related]
3. Rising cost of anticancer drugs in Australia.
Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
[TBL] [Abstract][Full Text] [Related]
4. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
5. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
Cohen J; Malins A; Shahpurwala Z
Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
[TBL] [Abstract][Full Text] [Related]
6. Realigning incentives for developing and pricing new anticancer treatments.
Howard DH
JAMA; 2011 Jun; 305(22):2347-8. PubMed ID: 21642689
[No Abstract] [Full Text] [Related]
7. Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs.
Kim SH; Ryu YJ; Cho NE; Kim AE; Chang J
Clin Drug Investig; 2017 Oct; 37(10):957-963. PubMed ID: 28735450
[TBL] [Abstract][Full Text] [Related]
8. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
9. Killing U.S. Slowly: Curing the Epidemic Rise of Cancer Drug Prices.
White EK
Food Drug Law J; 2017; 72(1):189-224. PubMed ID: 29140658
[TBL] [Abstract][Full Text] [Related]
10. The high price of anticancer drugs: origins, implications, barriers, solutions.
Prasad V; De Jesús K; Mailankody S
Nat Rev Clin Oncol; 2017 Jun; 14(6):381-390. PubMed ID: 28290490
[TBL] [Abstract][Full Text] [Related]
11. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
[TBL] [Abstract][Full Text] [Related]
12. Barriers to Ensuring Access to Affordable Prescription Drugs.
Mello MM
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():275-289. PubMed ID: 31136248
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
Gordon N; Stemmer SM; Greenberg D; Goldstein DA
J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
[TBL] [Abstract][Full Text] [Related]
14. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
Mailankody S; Prasad V
JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
[No Abstract] [Full Text] [Related]
15. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
16. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
Savage P; Mahmoud S; Patel Y; Kantarjian H
J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
[TBL] [Abstract][Full Text] [Related]
17. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.
Shih YT; Xu Y; Liu L; Smieliauskas F
J Clin Oncol; 2017 Aug; 35(22):2482-2489. PubMed ID: 28471711
[TBL] [Abstract][Full Text] [Related]
18. Specialty medications: traditional and novel tools can address rising spending on these costly drugs.
Lotvin AM; Shrank WH; Singh SC; Falit BP; Brennan TA
Health Aff (Millwood); 2014 Oct; 33(10):1736-44. PubMed ID: 25288417
[TBL] [Abstract][Full Text] [Related]
19. Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D.
Dusetzina SB
N Engl J Med; 2022 Jun; 386(23):2164-2167. PubMed ID: 35507526
[No Abstract] [Full Text] [Related]
20. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
[Next] [New Search]